Dusigitumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dusigitumab
Monoclonal antibody
Type Whole antibody
Source Human
Target ILGF2
Clinical data
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6372H9824N1700O2016S54
Molar mass 151 kg/mol

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2.[1] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[2]


References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dusigitumab, American Medical Association.
  2. ^ http://adisinsight.springer.com/drugs/800030209